论文部分内容阅读
目的:探讨CAG方案治疗老年急性髓系白血病的疗效及不良反应。方法:应用CAG方案即阿糖胞苷(Ara-c)10 mg/m2,每12 h 1次,皮下注射第1～14天;阿柔吡星(Acla)10 mg/(m2.d),静脉滴注,第1～8天;粒细胞集落刺激因子(G-CSF)300μg/d,皮下注射,第1～14天,治疗老年、难治急性髓系白血病15例。结果:总有效(CR+PR)率73.3%,8例取得完全缓解(CR),3例部分缓解(PR),不良反应有白细胞、红细胞、血小板减少所致的感染、贫血、出血等。结论:CAG方案治疗老年急性髓系白血病耐受性好,效果明显。
Objective: To investigate the efficacy and adverse reactions of CAG regimen in the treatment of senile acute myeloid leukemia. Methods: The CAG regimen was given with Ara-c 10 mg / m2 once every 12 hours for subcutaneous injection for days 1-14. Acla 10 mg / (m2.d) Intravenous drip, 1 to 8 days; granulocyte colony stimulating factor (G-CSF) 300μg / d, subcutaneous injection, the first to 14 days, the treatment of elderly, refractory acute myeloid leukemia in 15 cases. Results: The total effective rate (CR + PR) was 73.3%, complete remission (CR) was achieved in 8, partial remission in 3 (PR), and adverse reactions were leucocyte, erythrocyte, thrombocytopenia, anemia and hemorrhage. Conclusion: CAG regimen is effective in treating acute myeloid leukemia in aged patients with obvious effect.